Appili Therapeutics Inc (APLI) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.018x

Based on the latest financial reports, Appili Therapeutics Inc (APLI) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-293.07K ≈ $-212.00K USD) by net assets (CA$-16.38 Million ≈ $-11.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Appili Therapeutics Inc (APLI) defensive interval to measure how many days the company can operate on defensive assets alone.

Appili Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Appili Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Appili Therapeutics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Appili Therapeutics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Focusrite Plc LSE:TUNE	0.145x
Dragon Mountain Gold Ltd AU:DMG	-0.204x
Nusantara Inti Corpora Tbk JK:UNIT	-0.084x
Wang & Lee Group, Inc. Ordinary Shares NASDAQ:WLGS	0.051x
GGX Gold Corp V:GGX	0.054x
Bank Pembangunan Daerah Banten Tbk PT JK:BEKS	0.265x
Valora Effekten Handel AG F:VEH	N/A
elexxion AG XETRA:E8X	-708202.000x

Annual Cash Flow Conversion Efficiency for Appili Therapeutics Inc (2017–2025)

The table below shows the annual cash flow conversion efficiency of Appili Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Appili Therapeutics Inc (APLI) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	CA$-13.40 Million ≈ $-9.69 Million	CA$868.82K ≈ $628.49K	-0.065x	-128.75%
2024-03-31	CA$-10.92 Million ≈ $-7.90 Million	CA$-2.46 Million ≈ $-1.78 Million	0.226x	-83.48%
2023-03-31	CA$-7.40 Million ≈ $-5.35 Million	CA$-10.10 Million ≈ $-7.30 Million	1.365x	-76.60%
2022-03-31	CA$-3.27 Million ≈ $-2.37 Million	CA$-19.08 Million ≈ $-13.80 Million	5.834x	+749.77%
2021-03-31	CA$12.75 Million ≈ $9.23 Million	CA$-11.45 Million ≈ $-8.28 Million	-0.898x	-86.42%
2020-03-31	CA$8.85 Million ≈ $6.40 Million	CA$-4.26 Million ≈ $-3.08 Million	-0.482x	+38.42%
2019-03-31	CA$4.42 Million ≈ $3.20 Million	CA$-3.46 Million ≈ $-2.50 Million	-0.782x	-15.22%
2018-03-31	CA$4.87 Million ≈ $3.52 Million	CA$-3.30 Million ≈ $-2.39 Million	-0.679x	+56.34%
2017-03-31	CA$1.37 Million ≈ $994.41K	CA$-2.14 Million ≈ $-1.55 Million	-1.555x	--

About Appili Therapeutics Inc

TO:APLI Canada Biotechnology

Market Cap

$1.39 Million

CA$1.93 Million CAD

Market Cap Rank

#30288 Global

#1547 in Canada

Share Price

CA$0.02

Change (1 day)

+0.00%

52-Week Range

CA$0.01 - CA$0.04

All Time High

CA$1.87